<?xml version="1.0"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/"><rdf:Description rdf:about="https://repozitorij.uni-lj.si/IzpisGradiva.php?id=135709"><dc:title>The role of PI3K/AKT and MAPK signaling pathways in erythropoietin signalization</dc:title><dc:creator>Tóthová,	Zuzana	(Avtor)
	</dc:creator><dc:creator>Šemeláková,	Martina	(Avtor)
	</dc:creator><dc:creator>Solárová,	Zuzana	(Avtor)
	</dc:creator><dc:creator>Tomc,	Jana	(Avtor)
	</dc:creator><dc:creator>Debeljak,	Nataša	(Avtor)
	</dc:creator><dc:creator>Solár,	Peter	(Avtor)
	</dc:creator><dc:subject>erythropoietin</dc:subject><dc:subject>PI3K</dc:subject><dc:subject>MAPK</dc:subject><dc:description>Erythropoietin (EPO) is a glycoprotein cytokine known for its pleiotropic effects on varioustypes of cells and tissues. EPO and its receptor EPOR trigger signaling cascades JAK2/STAT5,MAPK, and PI3K/AKT that are interconnected and irreplaceable for cell survival. In this article, wedescribe the role of the MAPK and PI3K/AKT signaling pathways during red blood cell formationas well as in non-hematopoietic tissues and tumor cells. Although the central framework of thesepathways is similar for most of cell types, there are some stage-specific, tissue, and cell-lineagedifferences. We summarize the current state of research in this field, highlight the novel members ofEPO-induced PI3K and MAPK signaling, and in this respect also the differences between erythroidand non-erythroid cells.</dc:description><dc:date>2021</dc:date><dc:date>2022-03-29 11:49:51</dc:date><dc:type>Članek v reviji</dc:type><dc:identifier>135709</dc:identifier><dc:language>sl</dc:language></rdf:Description></rdf:RDF>
